Nalbuphine Serb (Nalbuphine Hydrochloride)

Nalbuphine, the active ingredient in Nalbuphine Serb, is an opioid analgesic presented as an injectable solution for intramuscular, intravenous, and subcutaneous use. It provides analgesia for moderate to severe acute pain, postoperative discomfort, and obstetric procedures in adult patients.

GNH USA supplies Nalbuphine Serb as a licensed, GDP‑compliant international pharmaceutical product to hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity across global markets.

Nalbuphine is used in the management of pain conditions that involve the opioid pathway.

- Moderate to severe acute pain: provides effective analgesia when other agents are insufficient. - Post‑operative pain: reduces pain intensity after surgical procedures. - Obstetric analgesia: offers pain relief during labor while limiting respiratory depression.

Nalbuphine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Nausea - Vomiting - Sedation - Headache - Sweating

Serious or Rare Side Effects: - Respiratory depression - Hypotension - Allergic reactions (rash, urticaria, anaphylaxis) - Severe sedation - Chest pain - Seizures

When prescribing Nalbuphine, clinicians should consider several safety measures to minimize risk.

- Assess respiratory function: monitor breathing, especially in patients with pulmonary disease. - Evaluate hepatic and renal function: adjust use in impairment. - Avoid concurrent central nervous system depressants: increased sedation risk. - Use caution in patients with a history of substance abuse: potential for misuse. - Pregnancy and lactation: weigh benefits against potential risks; limited data available. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Nalbuphine can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with other opioid agonists: may reduce analgesic effect and increase risk of respiratory depression. - Benzodiazepines or barbiturates: additive CNS depression. - MAO inhibitors: risk of severe hypotension and sedation.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate urinary retention. - Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome. - CYP3A4 inhibitors or inducers: may affect Nalbuphine metabolism.